Research Article
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
Figure 1
Spleen size distribution.
(a) Patients with low-risk MF () |
(b) Patients with intermediate-1-risk MF () |